Introduction
============

The status of internal mammary lymph nodes (IMLNs) plays an important role in completing staging, guiding clinical treatment, and judging prognosis as axillary lymph node (ALN) for breast cancer \[[@b1-crt-2018-062]-[@b3-crt-2018-062]\]. Until now, internal mammary lymph node irradiation (IMLNI) is based on the high risk of IMLNs metastasis \[[@b4-crt-2018-062]\] especially the pathology status of ALNs and the location of primary tumor \[[@b1-crt-2018-062],[@b5-crt-2018-062],[@b6-crt-2018-062]\]. However, this method could not accurately predict the metastasis in IMLN, might lead to some patients received over- or undertreatment, and also would restrict the application of IMLNI in the clinical practice. Currently, internal mammary sentinel lymph node biopsy (IM-SLNB) could efficiently evaluate the pathology status of internal mammary sentinel lymph node (IM-SLN) with high safety and feasibility \[[@b7-crt-2018-062],[@b8-crt-2018-062]\]. Due to the accuracy of IM-SLN has not been validated and the low visualization rate of IM-SLN has not been improved, the application of IM-SLNB is restricted and the development of IM-SLNB is far behind axillary sentinel lymph node biopsy (ASLNB).

The accuracy of the axillary sentinel lymph node (ASLN) and its lymphatic drainage pattern has been validated by axillary lymph nodes dissection (ALND) \[[@b9-crt-2018-062]-[@b11-crt-2018-062]\]. However, IMLNs dissection has been abandoned in that it could not improve the survival of patients \[[@b12-crt-2018-062]\]. Thus, the accuracy of IM-SLN could not been proved by this method. As IMLN could receive drainage from all quadrants of tumors \[[@b13-crt-2018-062]\] and almost only intraparenchymal lymph flowing to the internal mammary region \[[@b14-crt-2018-062],[@b15-crt-2018-062]\], so we hypothesized that IM-SLN could receive lymphatic drainage from not only the primary tumor area but also the entire breast parenchyma. Based on this hypothesis, a modified radiotracer injection technique (periareolar intraparenchymal, high volume, and ultrasound guidance) was established, which improves the visualization rate of IM-SLN significantly and helps to promote the research of IM-SLNB \[[@b14-crt-2018-062]\].

Based on the modified injection technique, a small particle size colloid radiotracer (^99m^Tc-Dextran 40, \< 30 nm, molecular weight 40 kD), which could move to the secondary lymph nodes, was injected into the parenchyma and observed the lymphatic drainage pattern in the breast by lymphoscintigraphy of single-photon emission computed tomography/computed tomography (SPECT/CT) to reflect the real lymphatic drainage of the breast from the aspects of the anatomy and physiology, and to provide more evidences to verify the concept of IM-SLN in this study.

Materials and Methods
=====================

The freeze-dried kit of Dextran was procured from Shihong Pharmaceutical Center (25 mg Dextran 40 \[40 kD\] and 0.25 mg SnCl~2~; Beijing, China). The Na^99m^TcO4 was provided by the Department of Nuclear Medicine, Shandong Cancer Hospital Affiliated to Shandong University (Jinan, China). The ^99m^Tc-Sulfur colloid, which is the common radiotracer for sentinel lymph node (SLN) biopsy in the clinical practice, was also provided by the Department of Nuclear Medicine. The methylene blue injection was procured from Jichuan Pharmaceutical Group Co., Ltd. (2 mL; Taixing, China). All chemicals and reagents were of analytical grade.

1. Radiolabeling Dextran 40
---------------------------

The freeze-dried kit of Dextran was solubilized with Na^99m^TcO4 (1-2 mL, 370-740 MBq) to radiolabel the Dextran 40. The reaction mixture was fully shaken and then rest for 15 minutes at room temperature. In the clinical practice, the radiochemical purity of the radiotracer must be greater than 90% tested by radio-thin layer chromatography (TLC).

2. Animal experiment
--------------------

Twenty-eight-week-old female BALB/c mice were ordered from Shandong University Laboratory Animal Center (Jinan, China). They were bred under specific pathogen-free conditions in the Basic Laboratory, Shandong Cancer Hospital Affiliated to Shandong University for 1 week. All mice were randomly divided into four groups (group 1, 2, 3, and 4), with six mice in each. After anesthesia with isoflurane, ^99m^Tc-Dextran 40 was injected subcutaneously into one hind footpad of mice of the experimental groups (group 1, 25 μCi; group 2, 50 μCi; and group 3, 250 μCi). ^99m^Tc-sulfur colloid (50 μCi, boiling 5 minutes) was injected subcutaneously into one hind footpad of mice in the control group (group 4). The injection point, background, SLN (popliteal), secondary lymph node (iliac), tertiary lymph node (renal), and contralateral SLN (popliteal) were detected by γ detector on the surface of skin to identify *in vivo* radionuclides counts. Each group was randomly separated into two subgroups. Subgroup A was observed at 2 hours continuously after injection and subgroup B was observed for 12 hours before sacrifice. Furthermore, methylthioninium chloride injection (50 μL) was injected into all hind footpads 30 minutes before sacrifice.

The mice were sacrificed via cervical dislocation and subjected to dissection, following blue vital dye lymph vessel draining from the injection point to the blue dyed lymph nodes ([Fig. 1](#f1-crt-2018-062){ref-type="fig"}). The injection point, background, popliteal lymph node, iliac lymph node, renal lymph node, contralateral popliteal lymph node, heart, liver, spleen, lung, and kidney were collected and *ex vivo* radionuclide counts were identified by a handheld γ detector (Neoprobe 2000, Johnson & Johnson, Dublin, OH).

3. Clinical experiment
----------------------

### 1) Enrollment of patients

From December 2015 to July 2017, patients with histologically proven clinical stage cT~1-4~N~0-3~M~0~ unilateral primary breast cancer treated at our breast cancer center were enrolled. Patients with inflammatory breast cancer, radiotherapy, prior ASLNB, or with a history of prior contralateral breast surgery were excluded.

### 2) Injection of radiotracers

All the patients received radio-labeled tracer injection intraparenchymally at the 6 and 12 o'clock positions 2.0-3.0 cm away from the nipple under ultrasonographic guidance 16-18 hours before surgery \[[@b14-crt-2018-062]\]. ^99m^Tc-labeled sulfur colloid (1.0-1.2 mL, 18.5-37 MBq) was injected in the breast with tumor, and ^99m^Tc-Dextran 40 (1.0-1.2 mL, 74-148 MBq) was injected into the healthy breast.

### 3) Dynamic lymphoscintigraphy

Planar dynamic single-photon emission computed tomography (SPECT; Philips BrightView XCT, Philips Healthcare, Best, The Netherlands) scintigrphatic images were obtained 40-60 minutes (40-60 frames, 60 seconds per frame) in both anterior and lateral projection focusing on the area of interest subsequently after radiotracers injection to detect the direction of the lymphatic drainage. The SPECT acquisition conditions were set as matrix, 128×128; zoom, 1; peak energy, 140 keV; window width, 20%. The direction of lymphatic channel could be identified on the monitor. The first "hot spot" on the lymphoscintigraphy, either in the internal mammary area or in the axilla area, was considered to be a SLN. The localization and the number of all visible focal accumulations of radioactivity were recorded to observe the lymphatic drainage pattern in breast.

### 4) SPECT/CT combination imaging

SPECT/CT was performed immediately after SPECT dynamic lymphscintigrapy to identify the location of ALNs and IMLNs. The SPECT/CT system consisted of a dual-head variable-angle gamma camera equipped with low-energy high-resolution collimators and a three-slice spiral CT scanner (120 kV, 20 mAs, 4 mm slices) optimized for rapid rotation. The CT scanning was low-dose and non-contrast in this study. SPECT acquisition (matrix 64×64, zoom 1.46×\[40.9\] cm, 140 keV) was performed using steps of 6 degree (10 seconds per view). Maximum intensity projections with a three-dimensional display were generated to localize SLNs in relation to anatomical structures. In addition, the SPECT/CT combination images were acquired again in the next day morning (about 1 hour before surgery) for about 11 minutes. In the tumor side, IM-SLN was detected by both the SPECT/CT and γ detector, patients with radioactive IM-SLN received IM-SLNB. All enrolled patients were followed up 1 month to observe the complications.

4. Data analysis
----------------

This was a descriptive study with an analysis of the frequency of the findings. The data were analyzed with the SPSS ver. 17.0 software package (SPSS Inc., Chicago, IL). Pearson chi-square test or Fisher exact test was used for categorical variables. All tests were two-sided, and p \< 0.05 was considered statistically significant.

5. Ethical statement
--------------------

The study has been approved by the Shandong Cancer Hospital Affiliated to Shandong University Ethics Committee (No. SDTHEC20130324) and all subjects signed an informed consent form.

The animal experiment has been approved by the Shandong Cancer Hospital Affiliated to Shandong University Animal Ethics Committee (No. SDTHEC20130324).

Results
=======

1. Synthesis of ^99m^Tc-Dextran 40
----------------------------------

The radiolabeling yield was \> 95% using the freeze-dried kit of Dextran and Na^99m^TcO4. The results of TLC analysis showed that Rf value 0-0.1, 0.3 for ^99m^Tc-Dextran 40, Na^99m^Tc-O4, respectively.

2. Animal experiment
--------------------

The model of lymphatic drainage in the hind leg was shown in the [Fig. 1](#f1-crt-2018-062){ref-type="fig"}. In the experimental groups, the sentinel (popliteal) lymph node, the secondary (iliac) lymph node, and the tertiary (renal) lymph node was detected by γ detector at 5±0.59 minutes, 6±0.64 minutes, and 6.5±0.55 minutes, respectively after ^99m^Tc-Dextran 40 injection. In subgroup A, the stained first, second, and third nodes removed could be detected *ex vivo* radionuclide counts after dissection ([Table 1](#t1-crt-2018-062){ref-type="table"}). The count of contralateral popliteal lymph node was nearly equal to the background. The first, second, and third nodes in subgroup B also could be detected *in vivo* radionuclide counts after 12-hour injection. The radionuclide counts increased with the increasing of radiation dose injection. *In vivo* radionuclide counts of kidney and liver detected in all experimental groups were higher than spleen and lung, and the counts were increasing as time going on, which indicated that the ^99m^Tc-Dextran 40 was metabolized by kidney and liver in mice. In the control group, *ex vivo* radionuclide counts were only detected in the sentinel (popliteal) lymph node ([Table 1](#t1-crt-2018-062){ref-type="table"}). Thus, ^99m^Tc-Dextran 40 could enter each-tier lymph nodes detected by the γ probe and show the whole lymphatic drainage pattern of the hind leg in mouse.

3. Clinical experiment
----------------------

### 1) Patient characteristics

A total of 30 patients with cT~1-4~N~0-3~M~0~ breast cancer treated in our breast cancer center were enrolled into this study, and the median age was 49.5 years (range, 34 to 65 years). All of the demographic and clinicopathologic characteristics were listed in [Table 2](#t2-crt-2018-062){ref-type="table"}.

### 2) Lymphatic drainage imaging in human body

In the breast with ^99m^Tc-Dextran 40 injection, the imaging of drainage lymph vessels could be detected by SPECT 4.5±0.12 minutes after injection. It showed that the small radiotracer could drain to the lymph vessels from the injection site to the area of axilla or internal mammary. There were no any complications and reactions after 1-month follow-up.

In the area of axilla, the visualization rate of ALN was 90% (27/30). The imaging of the first ALN (ASLN) could be detected by SPECT at 5.5±0.17 minutes after injection, and then the small tracer drained from ASLN to the second-tier ALN at 6.5±0.12 minutes after injection. The imaging showed that the lymphatic drainage was one-by-one from ASLN to the other ALNs ([Figs. 2](#f2-crt-2018-062){ref-type="fig"}-[](#f3-crt-2018-062){ref-type="fig"}[4](#f4-crt-2018-062){ref-type="fig"}).

In the area of internal mammary, the visualization rate of IMLNs was 50% (15/30). The first IMLN (IM-SLN) could be detected in the first to fourth intercostal, and the proportion of them was 6.7% (1/15), 33.3% (5/15), 46.7% (7/15), and 13.3% (2/15), respectively, and only one lymph vessel could be detected draining to the IM-SLN. The imaging of the IM-SLN could be detected by SPECT at 10.5±0.35 minutes after injection, and the second-tier IMLN could be detected from the IM-SLN at 15.4±0.21 minutes after injection. The lymph drainage was step by step in the IMLN chain ([Figs. 2](#f2-crt-2018-062){ref-type="fig"}-[](#f3-crt-2018-062){ref-type="fig"}[4](#f4-crt-2018-062){ref-type="fig"}).

In the breast with ^99m^Tc-labeled sulfur colloid injection, the visualization rate of IM-SLN was 23.3% (7/30). The success rate of IM-SLNB was 100% (7/7). The median number of IM-SLNs was 2 (total, 10; range, 1 to 3). The site of IM-SLNs concentrated in the second (40.0%, 4/10) and third (40.0%, 4/10) intercostal space. The median time-consuming of IM-SLNB was 10 minutes. The IM-SLN positive rate was 14.3% (1/7), combining with ALNs metastases.

Discussion
==========

The study of the lymphatic drainage in the breast found that the ipsilateral ALNs receive more than 75% of the breast lymph and ipsilateral IMLNs receive other lymph \[[@b15-crt-2018-062]\]. As the same with ALNs, IMLNs could receive lymphatic drainage from all quadrants of the breast including primary tumor area \[[@b13-crt-2018-062]\].

In the IMLN chain, there might be two types lymphatics drainage pattern: one is the lymph in different area of the breast drain into the same IMLN, then other IMLNs receive the lymph from it one by one ([Fig. 5](#f5-crt-2018-062){ref-type="fig"}); another is the lymph in different area of the breast draining into different IMLNs ([Fig. 6](#f6-crt-2018-062){ref-type="fig"}). Only the IMLN lymphatic drainage pattern accords with the former one, the concept of IM-SLN is accuracy, and the pathology status of IM-SLN could reflect the situation of the whole IMLN chain. If the IMLN lymphatic drainage pattern accords with the later one, the pathology status of IM-SLN could not reflect the situation of the whole IMLN chain.

Due to extend radical mastectomy (including IMLNs dissection) had been abandoned as it did not improve survival versus radical mastectomy in 1980s \[[@b12-crt-2018-062]\], the lymphatic drainage pattern of internal mammary area cannot be validated by this method. In 1786, Cruikshank and colleagues used the mercury to explore the lymphatics drainage in the breast \[[@b16-crt-2018-062],[@b17-crt-2018-062]\]. In 1903, Poirer and Cuneo discovered the anatomy of the lymphatic system in the breast by using oil painting dye to stain the lymphatics \[[@b18-crt-2018-062]\]. However, the lymphatics of breast found by these methods were identified in the cadaver and it did not describe the IMLN lymphatics drainage pattern in details. Suami used hydrogen peroxide to identify the lymph vessels which injected with a lead oxide mixture and radiographed to study the IMLN lymphatics drainage pattern \[[@b19-crt-2018-062]\], but the result was also identified in the cadaver and could not reflect the really lymphatics drainage pattern in human body. With the development of imaging technique, Turner-Warwick injected radioisotope gold (Au^198^) into tumor during surgery in breast cancer patients and found that both ALNs and IMLNs could receive lymphatic drainage from all quadrants of the breast \[[@b13-crt-2018-062]\]. While, due to the limitation of the tomography technology, dynamic lymphscintigrapy could not be applied and the IMLN lymphatic drainage pattern was not identified in this study. However, this study provided some important information for designing our study.

To explore the IMLN lymphatic drainage pattern and validate the accurate of the IM-SLN concept, one radiotracer with small particle size was injected into intra-parenchyma, and then performing dynamic lymphoscintigraphy to identify the intercostal location and the lymphatic drainage pattern of IMLNs. In our clinical experience, the vessel is visualized less often with ^99m^Tc-labeled sulfur colloid. Colloids with different particles size (e.g., unfiltered sulfur colloid, 50-1,000 nm) enter the lymphatic vessels slowly through pinocytosis; even larger particles do not migrate from the injection site \[[@b20-crt-2018-062]\]. Smaller particles (e.g., size \< 5 nm) could easily leak into the bloodstream directly \[[@b21-crt-2018-062]\]. However, particles size between 5 nm and 25 nm could enter lymphatic capillaries via the gaps between cell junctions and the intercellular clefts formed by overlapping cells, which often allows us to visualize the lymphatic drainage vessels leading directly to the lymph node in the lymphoscintigraphy \[[@b20-crt-2018-062]\]. ^99m^Tc-Dextran 40 (\< 30 nm) is a small particle colloid which has been proved in mice model. Based on the lymphatic drainage in the hind foot of mouse described by Harrell et al. \[[@b22-crt-2018-062]\], all blue dyed lymph nodes were caught by following the blue dyed draining lymph vessel. All dissected blue dyed lymph nodes have a high *ex vivo* radionuclide counts and the counts of second-tier lymph nodes were higher than 10% of the SLN. Thus, ^99m^Tc-Dextran 40 could drain into lymphatic vessels and make every tier lymph nodes imaging in the hind-foot of mouse.

The lymphoscintigraphy technique plays an important role in SLN biopsy and could show the lymphatic drainage vessels passing from the tumor site to the draining lymph node after radiotracer injection \[[@b23-crt-2018-062]\]. It could find an unequivocal channel entering the first lymph node (defined as SLN) in the SPECT dynamic lymphoscintigraphy. SPECT/CT camera fuses tomographic lymphoscintigrams with anatomical data from CT \[[@b24-crt-2018-062]\]. The combination images of SPECT/CT provide functional and anatomical images in the same scanning session and help to identify the intercostal location of IMLN ([Figs. 3](#f3-crt-2018-062){ref-type="fig"} and [4](#f4-crt-2018-062){ref-type="fig"}). SPECT/CT provides an anatomical overview in three-dimensional perspectives that cannot be provided by planar images or intraoperative lymphatic mapping techniques \[[@b25-crt-2018-062],[@b26-crt-2018-062]\].

The accuracy of ASLN has been validated by ALND \[[@b9-crt-2018-062]-[@b11-crt-2018-062]\]. The results of our study showed that the second-tier ALN received the lymphatic drainage vessel from the ASLN, which accord with the concept of ASLN ([Fig. 2](#f2-crt-2018-062){ref-type="fig"}). It indicated the accuracy of our method to identify the IMLN lymphatic drainage indirectly.

In our study, lymphatic vessel draining to internal mammary area could be detected by SPECT at 4.5±0.12 minutes after the ^99m^Tc-Dextran 40 injected intraparenchymally ([Fig. 2](#f2-crt-2018-062){ref-type="fig"}). The drainage lymphatic vessel was found from injection point to the first IMLN (IM-SLN) after 10.5±0.35 minutes radiotracer injection and the image of the IM-SLN became more and more clearly which means radiotracer was accumulating into the IM-SLN. After that, the imaging of SPECT showed the second IMLN received the lymph drainage from the IM-SLN and then the third IMLN received the lymph drainage from the second IMLN. Thus, the lymphatic drainage pattern was step by step in the internal mammary area. The location of the IM-SLN was concentrated in the second 33.3% (5/15) and third 46.7% (7/15) intercostal space. Therefore, the IMLN lymphatic drainage is accord with the model as showing by [Fig. 5](#f5-crt-2018-062){ref-type="fig"}. It demonstrated the accuracy of IM-SLN concept and the situation of IM-SLN could stand for the whole IMLN chain. This study provided more evidence to support that IM-SLN removed by IM-SLNB guiding with the modified radiotracer injection technique is true SLN in the IMLN chain. In our pilot study, we have demonstrated that the primary tumor area and the entire breast parenchyma could drain into the same IMLN \[[@b7-crt-2018-062]\]. Combined with the conclusion of the pilot study, we could conclude that IM-SLN receives lymphatic drainage from not only the primary tumor area, but also the entire breast parenchyma.

In conclusion, the lymphatic drainage pattern was presented by the small radiotracer (^99m^Tc-Dextran 40) on the lymphoscintigraphy of SPECT/CT. In the IMLN chain, the lymph was identified draining from different regions of the breast to IM-SLN, and then outward from IM-SLN to other IMLN one by one. It demonstrated the concept of the IM-SLN and provided more evidences for the application of IM-SLNB in the clinical practice.
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![The lymphatic drainage identified by blue dye in the hind foot of the mice. a, injection point; b, sentinel lymph node (popliteal); c, secondary lymph node (iliac); d, tertiary lymph node (renal).](crt-2018-062f1){#f1-crt-2018-062}

![The single-photon emission computed tomography images of dynamic lymphoscintigraphy. The small particle radiotracer could be identified in the lymphoscintigraphy with the time going. R, right breast is the tumor side; L, left breast is the sound side; IMLN, internal mammary lymph node; ALN, axillary lymph node; ASLN, axillary sentinel lymph node.](crt-2018-062f2){#f2-crt-2018-062}

![The combination images of single-photon emission computed tomography (SPECT)/computed tomography (CT) which helps to identify the intercostal location of internal mammary lymph nodes (IMLNs) from different anatomical aspects. ASLN, axillary sentinel lymph node.](crt-2018-062f3){#f3-crt-2018-062}

![The lymphoscintigraphy detected by the single-photon emission computed tomography (SPECT)/computed tomography (CT) in the next day morning about 1 hour before surgery. IMLN, internal mammary lymph node; ASLN, axillary sentinel lymph node; SCLN, supraclavicular lymph node.](crt-2018-062f4){#f4-crt-2018-062}

![The lymph in different area drain into the same internal mammary lymph node (IMLN), and then other IMLNs receive lymph from it one by one.](crt-2018-062f5){#f5-crt-2018-062}

![The lymph in different area of breast drain into different internal mammary lymph nodes.](crt-2018-062f6){#f6-crt-2018-062}

###### 

The *ex vivo* radionuclides counts of each-tier lymph nodes in subgroup A (n=12)

  Group            Radiotracer doses (uCi)   SLN         Second LN   Third LN   Contra-lateral SLN   Background
  ---------------- ------------------------- ----------- ----------- ---------- -------------------- ------------
  **Experiment**                                                                                     
   1               25                        120±1.5     56±1.6      48±2.6     10±1.7               8±1.2
   2               50                        620±1.2     129±1.7     186±1.9    16±1.2               15±1.5
   3               150                       1,032±1.3   424±1.5     402±1.5    48±1.2               27±1.3
  **Control**                                                                                        
   4               50                        550±1.1     0           0          0                    1±1.0

SLN, sentinel lymph node; LN, lymph node.

###### 

Clinical characteristics of the patients with (+) and without (--) IMLN imaging in the experimental side

  Characteristic             IMLN--   IMLN+   p-value
  -------------------------- -------- ------- ---------
  **Age (yr)**                                
   Median                    49.5             
   ≤ 50                      7        12      0.128
   \> 50                     8        3       
  **BMI (kg/m^2^)**                           
   18.5-24.9                 11       12      1.000
   25.0-28.0                 4        3       
   \> 28.0                   0        0       
  **Mammographic density**                    
   ACR 1                     6        1       0.074
   ACR 2                     6        10      
   ACR 3                     2        4       
   ACR 4                     1        0       

IMLN, internal mammary lymph node; BMI, body mass index; ACR, American College of Radiology (ACR 1; almost entirely fat, glandular tissue \< 25%; ACR 2, scattered fibroglandular densities \[ca. 25-50% of breast\]; ACR 3, heterogeneously breast dense \[ca. 51-75% of breast\]; and ACR 4, extremely dense \[\> 75% of breast\]).
